315 related articles for article (PubMed ID: 25612289)
1. [Response to Terlipressin and albumin is associated with improved outcome in patients with cirrhosis and hepatorenal syndrome].
Nguyen-Tat M; Götz E; Scholz-Kreisel P; Ahrens J; Sivanathan V; Schattenberg J; Rey JW; Wörns MA; Galle PR; Marquardt JU
Dtsch Med Wochenschr; 2015 Jan; 140(2):e21-6. PubMed ID: 25612289
[TBL] [Abstract][Full Text] [Related]
2. Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1.
Boyer TD; Sanyal AJ; Wong F; Frederick RT; Lake JR; O'Leary JG; Ganger D; Jamil K; Pappas SC;
Gastroenterology; 2016 Jun; 150(7):1579-1589.e2. PubMed ID: 26896734
[TBL] [Abstract][Full Text] [Related]
3. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study.
Martín-Llahí M; Pépin MN; Guevara M; Díaz F; Torre A; Monescillo A; Soriano G; Terra C; Fábrega E; Arroyo V; Rodés J; Ginès P;
Gastroenterology; 2008 May; 134(5):1352-9. PubMed ID: 18471512
[TBL] [Abstract][Full Text] [Related]
4. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study.
Ortega R; Ginès P; Uriz J; Cárdenas A; Calahorra B; De Las Heras D; Guevara M; Bataller R; Jiménez W; Arroyo V; Rodés J
Hepatology; 2002 Oct; 36(4 Pt 1):941-8. PubMed ID: 12297842
[TBL] [Abstract][Full Text] [Related]
5. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study.
Moreau R; Durand F; Poynard T; Duhamel C; Cervoni JP; Ichaï P; Abergel A; Halimi C; Pauwels M; Bronowicki JP; Giostra E; Fleurot C; Gurnot D; Nouel O; Renard P; Rivoal M; Blanc P; Coumaros D; Ducloux S; Levy S; Pariente A; Perarnau JM; Roche J; Scribe-Outtas M; Valla D; Bernard B; Samuel D; Butel J; Hadengue A; Platek A; Lebrec D; Cadranel JF
Gastroenterology; 2002 Apr; 122(4):923-30. PubMed ID: 11910344
[TBL] [Abstract][Full Text] [Related]
6. The efficacy and safety of terlipressin and albumin in patients with type 1 hepatorenal syndrome: a multicenter, open-label, explorative study.
Narahara Y; Kanazawa H; Sakamoto C; Maruyama H; Yokosuka O; Mochida S; Uemura M; Fukui H; Sumino Y; Matsuzaki Y; Masaki N; Kokubu S; Okita K
J Gastroenterol; 2012 Mar; 47(3):313-20. PubMed ID: 22038555
[TBL] [Abstract][Full Text] [Related]
7. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial.
Cavallin M; Kamath PS; Merli M; Fasolato S; Toniutto P; Salerno F; Bernardi M; Romanelli RG; Colletta C; Salinas F; Di Giacomo A; Ridola L; Fornasiere E; Caraceni P; Morando F; Piano S; Gatta A; Angeli P;
Hepatology; 2015 Aug; 62(2):567-74. PubMed ID: 25644760
[TBL] [Abstract][Full Text] [Related]
8. Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with Terlipressin: a retrospective analysis.
Colle I; Durand F; Pessione F; Rassiat E; Bernuau J; Barrière E; Lebrec D; Valla DC; Moreau R
J Gastroenterol Hepatol; 2002 Aug; 17(8):882-8. PubMed ID: 12164964
[TBL] [Abstract][Full Text] [Related]
9. The Treatment of Hepatorenal Syndrome.
Cavallin M; Fasolato S; Marenco S; Piano S; Tonon M; Angeli P
Dig Dis; 2015; 33(4):548-54. PubMed ID: 26159272
[TBL] [Abstract][Full Text] [Related]
10. Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome.
Nazar A; Pereira GH; Guevara M; Martín-Llahi M; Pepin MN; Marinelli M; Solá E; Baccaro ME; Terra C; Arroyo V; Ginès P
Hepatology; 2010 Jan; 51(1):219-26. PubMed ID: 19877168
[TBL] [Abstract][Full Text] [Related]
11. Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT-0401 and REVERSE randomised clinical studies.
Sanyal AJ; Boyer TD; Frederick RT; Wong F; Rossaro L; Araya V; Vargas HE; Reddy KR; Pappas SC; Teuber P; Escalante S; Jamil K
Aliment Pharmacol Ther; 2017 Jun; 45(11):1390-1402. PubMed ID: 28370090
[TBL] [Abstract][Full Text] [Related]
12. Terlipressin in 30 patients with hepatorenal syndrome: results of a retrospective study.
von Kalckreuth V; Glowa F; Geibler M; Lohse AW; Denzer UW
Z Gastroenterol; 2009 Jan; 47(1):21-6. PubMed ID: 19156588
[TBL] [Abstract][Full Text] [Related]
13. Terlipressin and albumin combination treatment in hepatorenal syndrome.
Danalioglu A; Cakaloglu Y; Karaca C; Aksoy N; Akyuz F; Ozdil S; Demir K; Besisik F; Boztas G; Mungan Z; Kaymakoglu S; Okten A
Hepatogastroenterology; 2003 Dec; 50 Suppl 2():ccciii-cccv. PubMed ID: 15244209
[TBL] [Abstract][Full Text] [Related]
14. Terlipressin and albumin combination treatment in patients with hepatorenal syndrome type 2.
Nguyen-Tat M; Jäger J; Rey JW; Nagel M; Labenz C; Wörns MA; Galle PR; Marquardt JU
United European Gastroenterol J; 2019 May; 7(4):529-537. PubMed ID: 31065370
[TBL] [Abstract][Full Text] [Related]
15. Terlipressin therapy for renal failure in cirrhosis.
Triantos CK; Samonakis D; Thalheimer U; Cholongitas E; Senzolo M; Marelli L; Leandro G; Patch D; Burroughs AK
Eur J Gastroenterol Hepatol; 2010 Apr; 22(4):481-6. PubMed ID: 19952764
[TBL] [Abstract][Full Text] [Related]
16. Reversal of hepatorenal syndrome in cirrhotic patients with terlipressin plus albumin. First experience in Mexico.
Muñoz LE; Alcalá EG; Cordero P; Martínez MA; Vázquez NY; Galindo S; Mendoza E; Segura JJ
Ann Hepatol; 2009; 8(3):207-11. PubMed ID: 19841499
[TBL] [Abstract][Full Text] [Related]
17. Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome.
Neri S; Pulvirenti D; Malaguarnera M; Cosimo BM; Bertino G; Ignaccolo L; Siringo S; Castellino P
Dig Dis Sci; 2008 Mar; 53(3):830-5. PubMed ID: 17939047
[TBL] [Abstract][Full Text] [Related]
18. Terlipressin Improves Renal Function and Reverses Hepatorenal Syndrome in Patients With Systemic Inflammatory Response Syndrome.
Wong F; Pappas SC; Boyer TD; Sanyal AJ; Bajaj JS; Escalante S; Jamil K;
Clin Gastroenterol Hepatol; 2017 Feb; 15(2):266-272.e1. PubMed ID: 27464593
[TBL] [Abstract][Full Text] [Related]
19. High age and low sodium urine concentration are associated with poor survival in patients with hepatorenal syndrome.
Hinz M; Wree A; Jochum C; Bechmann LP; Saner F; Gerbes AL; Gerken G; Canbay A
Ann Hepatol; 2013; 12(1):92-9. PubMed ID: 23293199
[TBL] [Abstract][Full Text] [Related]
20. Terlipressin and albumin for type-1 hepatorenal syndrome associated with sepsis.
Rodríguez E; Elia C; Solà E; Barreto R; Graupera I; Andrealli A; Pereira G; Poca M; Sánchez J; Guevara M; Soriano G; Alessandria C; Fernández J; Arroyo V; Ginès P
J Hepatol; 2014 May; 60(5):955-61. PubMed ID: 24447876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]